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Introduction: Epidemiologic data indicate diabetes confers an augmented risk of lung
cancer development, yet the relationship between hyperglycemia, metabolic agents, and
prognosis is unclear. We analyzed the impact of hyperglycemia, anti-diabetic agents,
and statins on outcomes in non-small cell lung cancer (NSCLC) patients undergoing
chemoradiation.
Method and Materials: In total, data from 170 patients with stage III NSCLC treated at
the University of Pittsburgh Medical Center between 2001 and 2014 were obtained for
analysis. Kaplan-Meier survival analysis was used to estimate time-to-event for overall
survival (OS), disease-free survival, distant metastasis (DM), and loco-regional control
(LRC). Blood glucose values (n= 2870), statins, and diabetic medications were assessed
both continuously and categorically in univariable and multivariable Cox proportional
hazard regression models to estimate hazard ratios and identify prognostic factors.
Results: Tumor volume was a negative prognostic factor for OS, disease-free survival,
DM, and LRC (p = 0.001). Tumor stage and treatment time were associated with
increased all-cause mortality. Any glucose measurement ≥ 130 mg/dl during treatment
(2-year estimate 49.9 vs. 65.8%, p = 0.095) was borderline significant for decreased
LRC, with similar trends on multivariable analysis (HR 1.636, p = 0.126) and for
OS (HR 1.476, p = 0.130). Statin usage was associated with improved 2-year
LRC (53.4 vs. 62.4%, p = 0.088) but not with improvements in survival. Other
glycemic parameters, comorbid diabetes diagnosis, or anti-diabetic medications were
not significantly associated with outcomes.
Conclusions: There were trends for blood glucose value over 130 mg/dl and statin
nonuse being associated with inferior prognosis for LRC in stage III NSCLC patients;
glycemic state, statin usage, and glucose-modulating medications were not associated
with survival outcomes in multivariable analysis in this retrospective database.
Keywords: lung cancer, blood glucose, chemotherapy, radiation therapy, metformin, statins, tumor metabolism
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INTRODUCTION
Lung cancer is the leading cause of cancer mortality globally
(1). While non-small cell lung cancer (NSCLC) comprises 85%
of lung cancer cases in the United States, survival rates remain
dismal. The 5-year overall survival rate for NSCLC is 21% (2),
illustrating the need for better treatment options.
Diabetes has been implicated as a risk factor for cancer
development at multiple sites including the pancreas, esophagus,
liver, colon, and breast (3, 4). Insulin, a mitogenic hormone,
is elevated in the setting of type 2 diabetes. By both binding
its receptor and increasing bioavailability of insulin-like growth
factor 1 (IGF-1), these peptides are free to exhibit potent
anti-apoptotic and cell proliferative effects. Additionally, given
glucose’s efficacy in stimulating expression of the insulin
receptor (IR) as well as modulating its affinity for insulin,
hyperglycemia, and hyperinsulinemia are speculated to promote
cancer development and proliferation via activation of IR and
downstream provocation of the PI3K-Akt-mTORC1 and MAPK
pathways (5, 6) Furthermore, proliferation of lung cancer
cells correlates with uptake of the glucose-based tracer [F-18]
fluorodeoxyglucose during positron emission tomography (PET)
scans (7). Yet, it remains unclear if an elevated blood glucose
could enhance tumor metabolism and affect clinical outcomes in
this manner.
Hyperglycemia has reliably been associated with a poorer
prognosis in other cancers, yet the effect of hyperglycemia on
survival in lung cancer patients undergoing definitive treatment
with chemoradiation is unknown (8, 9). To our knowledge,
only three studies have described the effect of fasting serum
glucose on survival in NSCLC; all found elevated serum glucose
levels to be associated with diminished overall survival (10–
12). However, other studies have reported that diabetes-induced
microangiopathy may protect vascular basal membranes from
tumor cell digestion, thus interfering with neoplastic cell spread
and improving survival (13).
Other data implicate the utilization of cholesterol for cancer
metabolism, exemplified by associations between low serum
cholesterol and protection from cancer development (14).
Statins, which inhibit 3-hydroxy-3-methylglutaryl coenzyme A
(HMG-CoA) reductase, exhibit pleotropic effects. Experimental
studies have demonstrated cytotoxic effects in cancer cells
stemming from increased intracellular reactive oxygen species
(ROS) production (15), altered protein expression (16, 17),
and potential radiosensitizing effects (18). Simvastatin has
been shown to decrease Bcl-2 expression, increase Bax protein
expression, and halt G1-S cell cycle progression in human lung
cancer cells in a dose-dependent manner (19). Recent studies
have revealed evidence for enhanced survival in statin users at
various sites including prostate (20), colorectal (21), and breast
cancer (22). We previously reported improved mortality and
distant metastases in advanced-stage pancreatic cancer patients
using statin medications (23).
The role hyperglycemia, antidiabetics, and statins play in
lung cancer prognosis has not been fully elucidated. In this
study, we examine the effect of serum glucose levels before,
during, and after treatment, along with statins and anti-diabetic
medication exposure on overall survival, disease-free survival,
distant metastasis, and loco-regional control in patients with
stage III NSCLC treated with definitive chemoradiation.
MATERIALS AND METHODS
Patient Population
After institutional review board approval, we retrospectively
evaluated the medical records of all patients diagnosed with
stage III NSCLC, determined to have unresectable disease, and
treated with definitive chemoradiation with curative intent at
the University of Pittsburgh Medical Center between 2001 and
2014. Tumor staging was conducted in accordance with the
American Joint Committee on Cancer (AJCC) seventh edition.
Patients received daily radiotherapy treatment concurrently with
platinum-based doublet chemotherapy.
Measures
Patient characteristics and clinical laboratory values were
obtained from hospital records; including age, race, gender,
pre-radiotherapy body mass index (BMI), comorbidities,
medications, and chemotherapeutic agents. All serum glucose
values available in the electronic medical record were initially
collected. These values were non-fasting, random blood draws.
In many cases glucose was assessed at numerous time points
during the day and patients were therefore in differing glycemic
states. To reduce the impact of this bias, we included all glucose
values (n = 2870) spanning from 90 days prior to 90 days post
chemoradiation for analysis. We then grouped these values
into time points 1, 2, and 3, defined as within 90 days prior to
radiotherapy, during radiotherapy, and within 90 days post-
radiotherapy, respectively. Maximum, median, and minimum
serum glucose values at the preceding time points were analyzed
as continuous variables in univariable analysis with respect to
overall survival, disease-free survival, distant metastasis, and
loco-regional control.
Additionally, at each time point we stratified the maximum
blood glucose value achieved into four levels: ≥130 mg/dl,
≥150 mg/dl, ≥175 mg/dl, and ≥200 mg/dl. Values were selected
based on normal lab cutoff values, previous results (10), and to
provide ample data points for thorough analysis. Univariable Cox
regression was again conducted to assess the effect maximum
blood glucose value has on our primary outcomes of interest.
Serum blood glucose at the aforementioned time points was
considered the main prognostic factor of interest.
Prior literature has recommended the use of a lag period in
observational cancer studies (24), after which patients switch
from the non-exposed to exposed group. Similar reports have
found a lag period of 6 months to be an appropriate time
span (21), and to mitigate risk of reverse-causation bias, we
considered patients in the statin exposure group after 6 months
of continuous statin therapy. Previous studies have collected
cumulative statin dose in order to evaluate the prospect of a dose-
response relationship between dose and cancer-specific outcomes
(25). Furthermore, earlier investigations have explored various
pharmacologic properties of individual statin agents, namely
potency and lipophilicity status, as potential factors influencing
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clinical outcomes at other sites (26). To evaluate these potential
relationships in NSCLC patients we collected simvastatin and
atorvastatin dosages, standardized to simvastatin equivalents,
and stratified dosages into intensity interval groups. However,
as simvastatin was the predominant prescription agent, and
statin doses were sporadically recorded, they were excluded from
analysis, and stratification of therapeutic agents for individual
analysis was omitted.
Statistical Analysis
Overall survival, disease-free survival, freedom from distant
metastasis, and loco-regional control were the primary outcomes
measured. Loco-regional control was defined as the absence of
disease progression seen on follow-up imaging or primary and/or
regional lymph node biopsy. Kaplan-Meier survival analysis
was conducted to estimate the actuarial event probability
for each outcome. Select variables were assessed, including
patient characteristics, comorbidities, medications, tumor
characteristics, radiation therapy planning details, and treatment
time. Those achieving or approaching statistical significance
on univariable survival analysis (p < 0.10) were considered for
multivariable Cox regression while additionally including any
glucose measurement ≥130 during RT and glucocorticoid use
as main variables of interest. In addition, given recent findings
that glucocorticoids increase radioresistance in glioblastoma
cells and given their property to elevate blood glucose levels, we
included glucocorticoid usage in all multivariable models besides
a measure of blood glucose (27, 28). Hazard ratios were then
calculated to determine the magnitude of the effect. P-values <
0.05 and < 0.1 were considered as statistically “significant” and
“trending”, respectively. All statistical analyses were done using
IBM SPSS Statistics Version 23 (IBM, Armonk, NY).
RESULTS
Patient Characteristics
We identified 576 patients with newly diagnosed stage IIIA or
IIIB NSCLC, among which those treated surgically (n = 28)
or with palliative intent (n = 296) were excluded. Patients
receiving radiation therapy without concurrent chemotherapy
(n = 39) were also excluded. Of the remaining 213 patient
cohort, 43 patients were lost to follow up directly after treatment,
leaving 170 patients. Our study cohort was composed of 110
males (64.7%) and 60 females (35.3%). The median age of
subjects included for analysis was 67 years. The majority
of patients were diagnosed with stage IIIA NSCLC (57.6%)
and received chemotherapy as carboplatin-paclitaxel (87.6%).
Associated major comorbid states in this cohort were as follows:
diabetes mellitus (28.2%), coronary artery disease (11.2%),
hyperlipidemia (31.8%), and hypertension (44.7%). Comorbidity
prevalence in this cohort was comparable to a recent population
based study reporting major comorbidity prevalence in the
United States (29). A detailed description of patient, disease, and
treatment characteristics is presented in Table 1.
Median blood glucose values per patient did not substantially
change throughout the course of treatment. Among individual
patient median glucose values, the median measurements within
TABLE 1 | Patient, disease and treatment characteristics (n = 170).
PATIENT CHARACTERISTICS
Age, years
Median (range)
67 (38–91)
GENDER
Male 110 (64.7%)
Female 60 (35.3%)
Race
Caucasian 137 (80.6%)
African American 33 (19.4%)
Body mass index
Median (range) 26.2 (16.0–55.1)
Normal 33%
High 62%
Comorbidities
Diabetes 48 (28.2%)
Coronary artery disease 19 (11.2%)
Hyperlipidemia 54 (31.8%)
Hypertension 76 (44.7%)
Medications taken at the time of treatment
Metformin 9 (5.3%)
Sulfonylurea 9 (5.3%)
Insulin 44 (25.9%)
Statin 53 (31.2%)
Glucocorticoid 72 (42.4%)
DISEASE CHARACTERISTICS
Histology
Squamous cell 54 (31.8%)
Adenocarcinoma 77 (45.3%)
Large cell neuroendocrine 10 (5.9%)
Mixed 2 (1.2%)
Not otherwise specified 27 (15.9%)
T stage
T0 16 (9.4%)
T1 32 (18.8%)
T2 53 (31.2%)
T3 26 (15.3%)
T4 43 (25.3%)
N stage
N0 10 (5.9%)
N1 6 (3.5%)
N2 102 (60.0%)
N3 52 (30.6%)
AJCC stage (7th edition)
IIIA 98 (57.6%)
IIIB 72 (42.4%)
TREATMENT CHARACTERISTICS
Chemotherapy regimen
Carboplatin/paclitaxel 149 (87.6%)
Cisplatin/etoposide 5 (2.9%)
Carboplatin/pemetrexed 2 (1.2%)
Carboplatin/etoposide 5 (2.9%)
Carboplatin/docetaxel 3 (1.8%)
(Continued)
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TABLE 1 | Continued
PATIENT CHARACTERISTICS
Cisplatin/docetaxel 3 (1.8%)
Carboplatin/nab-
paclitaxel
1 (0.6%)
Cisplatin/gemcitabine 1 (0.6%)
Unknown 1 (0.6%)
Radiation technique
3D conformal 117 (68.8%)
IMRT 48 (28.2%)
Unknown 5 (2.9%)
GTV volume (cc)
Median (range) 84.7 (4.4–586.4)
PTV volume (cc)
Median (range) 340.0 (43.0–1303.0)
Cumulative radiation dose (Gy)
Median (IQ range) 72 (68.4–77.3)
Dose per fraction (Gy/fraction)
Median (IQ range) 2.0 (2.0–2.1)
Number of elapsed days for radiation treatment
Median (IQ range) 52 (49–56)
90 days prior to radiation, during radiation, and within 90 days
post-radiation therapy were 106.8 mg/dl, 106.0 mg/dl, and 111.0
mg/dl, respectively (Table 2).
Univariable Analyses
With a median follow up time of 24.2 months (range, 3.2–148.4),
the 2-year Kaplan-Meier estimates were as follows: locoregional
control 56.5% (95% CI 48.3–64.7%), distant metastasis rate
54.8% (95% CI 46.4–63.2%), disease-free survival 30.6% (95% CI
23.5–37.7%), and overall survival 55.1% (95% CI, 47.5–62.7%)
(Figure 1A).
Gross tumor volume (GTV) and planning target volume
(PTV) were consistent significant predictors associated with
all outcomes as continuous variables (Table 3). Patients with
any blood glucose value ≥130 mg/dL during treatment trended
toward worse locoregional control (2-year estimate 49.9 vs.
65.8%, p = 0.095) (Figure 1B). No other glucose parameters
(median, minimum, maximum, or any value with variable
cut-offs) were significantly associated with outcomes. Other
significant associations included prolonged treatment time with
inferior overall survival (unadjusted HR 1.020, p = 0.044),
stage IIIB disease with inferior disease-free survival (43.1
vs. 63.6%, p = 0.021) and overall survival (26.4 vs. 33.6%,
p = 0.085), and glucocorticoid usage during treatment with
improved overall survival (59.1 vs. 51.4%, p = 0.056). No other
glucose-modulating medications were significantly associated
with outcomes.
In unadjusted analysis (Table 3), baseline statin use was not
associated with enhanced overall survival (p = 0.673), freedom
from distant metastasis (p = 0.448), or disease-free survival
(p = 0.636). Baseline statin usage trended with improved 2-year
locoregional control (53.4 vs. 62.4%, p= 0.088).
Multivariable Analyses
Significant variables from univariable analysis plus the main
variables of interest were subjected to multivariable Cox
regression to identify independent prognostic factors. After
controlling for other potential confounding variables, increasing
PTV volume was correlated with inferior outcomes for all
endpoints (Table 4). Having any glucose measurement ≥130
mg/dL during chemoradiotherapy was associated with inferior
outcomes, reaching borderline significance for locoregional
control (adjusted HR 1.636, p = 0.126) and overall survival
(adjusted HR 1.476, p= 0.130).
DISCUSSION
In this retrospective-cohort study, we assessed the effect blood
glucose, anti-diabetics, and statin medications may have on
outcomes in newly diagnosed stage III NSCLC patients. Using
our retrospective data set with an extensive number of glucose
values, we observed that a glucose value ≥ 130 mg/dL trended
with diminished locoregional control and overall survival, while
statin usage trended with improved locoregional control. We
were otherwise unable to establish a substantial relationship
between blood glucose, anti-diabetic medication, or statin use
and any of the aforementioned time points and cancer-specific
outcomes. To our knowledge, this is the largest study to explore
these interactions in a strict NSCLC cohort.
As expected, tumor stage and size were significant prognostic
factors, and prolonged treatment time was associated with
increased mortality, all of which have been shown to correlate
with poorer outcomes previously (30, 31). In addition, contrary
to other data, body mass index was not associated with prognosis
in this cohort (32). Although our data suggest that glucocorticoid
usage at or before diagnosis may be associated with improved
overall survival, this was not supported in multivariable analysis
and may have simply been an artifact of the data.
A growing body of literature suggests that hyperglycemia may
behave as a prognostic factor in cancer outcomes, including in
cancer sites like high-grade gliomas, which has been inversely
proportional to serum glucose in multiple studies (33–36).
Early investigations exploring the relationship between diabetes
and overall survival in NSCLC reported longer survival times
in patients with diabetes (37), based on work suggesting
that diabetic microangiopathy may prevent the spread of
tumor cells (13). More recent literature yields evidence for
positive (38), negative (10, 39), and non-significant negative
associations (40) between diabetes and survival. We observed
no relationship between diabetes and overall survival nor distant
metastasis, suggesting that there is no clear evidence to support
microangopathy as a contributory factor to protection against
degradative tumor enzymes and distant metastasis.
Preclinical data demonstrates that inhibition of PI3K (41), Akt
(42), and mTOR (43) via molecular antagonists reduces tumor
growth and proliferation in murine models. Hyperglycemia
enhances WNT/β-catenin signaling in tumor cells (44), which is
associated with chemo- and radiotherapy resistance in NSCLC
(45). While preclinical data suggest that cancer treatment may be
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TABLE 2 | Glucose values (n = 2870) measured prior to, during and after chemoradiation.
Within 90 days prior
to radiation
During radiation Within 90 days
after radiation
Number of glucose measurements per patient
Median (range), mg/dL 2 (0–67) 6 (0–43) 3 (0–124)
Median glucose measurement per patient
Median (range), mg/dL 106.8 (52.5–269.0) 106.0 (79.0–317.0) 111.0 (63.0–241.9)
Minimum glucose measurement per patient
Median (range), mg/dL 95.0 (47.0–168.0) 91.0 (57.0–237.0) 94.5 (36.0–172.0)
Maximum glucose measurement per patient
Median (range), mg/dL 120.5 (81.0–500.0) 132.0 (88.0–355.0) 138.0 (82.0–469.0)
Number of patients with any glucose value:
≥130 mg/dL, n(%) 50 (29.4%) 60 (35.3%) 58 (34.1%)
≥150 mg/dL, n(%) 32 (18.8%) 50 (29.4%) 49 (28.8%)
≥175 mg/dL, n(%) 23 (13.5%) 30 (17.6%) 35 (20.6%)
≥200 mg/dL, n(%) 18 (10.6%) 17 (10.0%) 26 (15.3%)
FIGURE 1 | (A) Kaplan-Meier estimated locoregional control, distant metastasis rate, and overall survival for all patients. (B) Kaplan-Meier estimates of locoregional
control between groups with any serum glucose reading below or ≥130 mg/dL during the course of radiotherapy (p = 0.095).
enhanced via inhibiting these proteins with antagonist molecules,
downregulation by means of intense lifestyle changes, dietary
alterations, or modulation of insulin/glucose through diabetic
medication remains less clear in practice (5, 6). In other sites
blood glucose and/or insulin reduction via metformin, or a
ketogenic diet is being attempted to potentially offset these
glucose-fueled pathways (46–49). Still, preclinical data reveal
that tumors with PI3K activation may be resistant to dietary
restriction (50). While metformin usage has been associated with
improvements in survival in advanced stage lung cancer patients,
our data revealed no apparent benefit (51).
In contrast to earlier findings (10), we did not observe
a relationship between serum glucose and survival after
comprehensive statistical analysis, except for borderline
significance in univariable analysis. The reasons for this are
less clear, however, Luo et al. noted that 82.8% of their study
population consisted of advanced stage (stage IIIB or IV) NSCLC
patients in comparison to our 42.4% stage IIIB population.
Advanced stage disease could correlate with insulin resistance
and hence increased blood glucose, a phenomena of metabolic
dysregulation and cachexia that is not uncommon in these
patients (52). Another possible explanation for these differing
results may be a lack of adequate data points in the preceding
study, with the present study assessing 2870 glucose values
versus 342 in the other. Moreover, the above study also failed to
account for glucocorticoid usage, which would be required in
patients presenting with severe disease symptoms, thus offering
a considerable confounding factor.
Data on the benefit of statins in improving outcomes in lung
cancer patients remainmixed. Similar to our study, a recent phase
II clinical trial in 106 advanced-stage NSCLC (stage IIIB or IV)
revealed a weak, non-significant survival improvement in a group
that received gefitinib plus simvastatin compared to gefitinib
alone (53). A retrospective study revealed survival benefits
from statin usage in epidermal growth factor positive NSCLC,
however, they did not account for reverse-causation bias (54).
Another population-based cohort study noted a 12% reduction in
the rate of lung-cancer specific mortality in NSCLC and small cell
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TABLE 3 | Univariable survival analysis for various endpoints (Kaplan Meier survival differences and/or Cox regression hazard ratios included for significant or borderline
significant results).
Locoregional control
p (2y estimate/HR)
Distant metastasis
p (2y estimate/HR)
Overall survival
p (2y estimate/HR)
Disease-free survival
p (2y estimate/HR)
Age (continuous) 0.642 0.477 0.609 0.811
Gender 0.139 0.780 0.424 0.486
Race 0.797 0.549 0.813 0.697
BMI (continuous) 0.136 0.269 0.780 0.543
Comorbidities
Diabetes 0.132 0.833 0.808 0.650
Coronary artery disease 0.257 0.523 0.706 0.772
Hyperlipidemia 0.180 0.509 0.337 0.671
Hypertension 0.532 0.847 0.807 0.434
Medications
Metformin 0.293 0.650 0.206 0.808
Sulfonylurea 0.182 0.711 0.406 0.653
Insulin 0.171 0.650 0.738 0.851
Statin 0.088 (53.4 vs. 62.4%) 0.448 0.673 0.636
Glucocorticoid 0.200 0.944 0.056 (51.4 vs. 59.1%) 0.297
Histology 0.668 0.561 0.720 0.425
Stage 0.929 0.105 0.021 (63.6 vs. 43.1%) 0.085 (33.6 vs. 26.4%)
Radiation Technique 0.778 0.674 0.319 0.895
GTV volume (continuous) 0.006 (HR 1.004) 0.012 (HR 1.003) 0.002 (HR 1.003) 0.001 (HR 1.003)
PTV volume (continuous) 0.003 (HR 1.002) <0.001 (HR 1.002) <0.001 (HR 1.002) <0.001 (HR 1.002)
Cumulative radiation dose (continuous) 0.826 0.534 0.781 0.734
Number of elapsed days on treatment (continuous) 0.539 0.893 0.044 (HR 1.020) 0.447
Median glucose value (continuous)
Pre-treatment 0.397 0.541 0.463 0.392
During treatment 0.488 0.691 0.593 0.977
Post-treatment 0.317 0.520 0.346 0.762
Minimum glucose value (continuous)
Pre-treatment 0.480 0.206 0.366 0.494
During treatment 0.394 0.506 0.745 0.616
Post-treatment 0.161 0.686 0.296 0.676
Maximum glucose value (continuous)
Pre-treatment 0.369 0.842 0.297 0.306
During treatment 0.940 0.675 0.331 0.459
Post-treatment 0.819 0.498 0.530 0.821
Any pre-treatment glucose value
≥130 mg/dL 0.630 0.874 0.847 0.734
≥150 mg/dL 0.443 0.974 0.757 0.531
≥175 mg/dL 0.110 0.765 0.168 0.156
≥200 mg/dL 0.234 0.930 0.338 0.306
Any treatment glucose value
≥130 mg/dL 0.095 (49.9 vs. 65.8%) 0.493 0.939 0.840
≥150 mg/dL 0.643 0.666 0.595 0.797
≥175 mg/dL 0.321 0.877 0.396 0.570
≥200 mg/dL 0.386 0.518 0.918 0.878
Any post-treatment glucose value
≥130 mg/dL 0.958 0.390 0.274 0.518
≥150 mg/dL 0.829 0.451 0.138 0.560
≥175 mg/dL 0.564 0.911 0.976 0.506
≥200 mg/dL 0.704 0.680 0.920 0.750
Bold values statistically significant.
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TABLE 4 | Multivariable Cox regression survival analyses using forward
conditional analysis (p < 0.10 for model inclusion).
Variable Adjusted HR (95% CI) p
LOCOREGIONAL CONTROL
PTV volume (cc) 1.002 (1.001–1.003) 0.002
Glucose measurement ≥130 during RT 1.636 (0.871–3.070) 0.126
Glucocorticoid use 0.786 (0.430–1.436) 0.434
Statin use 0.806 (0.423–1.536) 0.512
DISTANT METASTASIS-FREE
PTV volume (cc) 1.002 (1.001–1.003) <0.001
Glucose measurement ≥130 during RT 1.301 (0.739–2.289) 0.362
Glucocorticoid use 1.000 (0.573–1.746) 1.000
Stage
IIIA 1.000 (Reference)
IIIB 0.722 (0.371–1.406) 0.338
OVERALL SURVIVAL
PTV volume (cc) 1.001 (1.000–1.002) 0.007
Glucose measurement ≥130 during RT 1.476 (0.892–2.442) 0.130
Glucocorticoid use 0.640 (0.385–1.063) 0.085
Stage
IIIA 1.000 (Reference)
IIIB 1.460 (0.846–2.519) 0.174
Treatment duration (days) 1.019 (0.988–1.050) 0.229
Radiation dose (Gy) 0.966 (0.921–1.013) 0.155
DISEASE-FREE SURVIVAL
PTV volume (cc) 1.002 (1.001–1.003) <0.001
Glucose measurement ≥130 during RT 1.112 (0.706–1.750) 0.646
Glucocorticoid use 0.890 (0.569–1.391) 0.608
Stage
IIIA 1.000 (Reference)
IIIB 1.297 (0.802–2.096) 0.289
Bold values statistically significant.
cancer patients using statins before diagnosis, including a trend
in the reduction of lung-cancer specific mortality with statin use
after diagnosis (55).
Small cell lung cancer malignancies are significantly more
radiosensitive, and statins impede progression from G1-S in the
cell cycle, potentially explaining the discrepancy between results
(56). On a cellular level, these changes would confer a potential
radiosensitizing effect to act synergistically with local treatment
and potentially enhance radiation response. Furthermore, statins
can mimic mutant p53 depletion and arrest cells in G1 by
halting cell cycle progression, both of which may enhance
radiosensitizing effects (57–59).
We cannot infer whether these mechanisms would influence
our results as well, but the finding that statin usage was associated
with improved locoregional control (p = 0.088 in univariable
analysis) would be consistent with them.
Inherent to observational studies, the risk of both
confounding and reverse-causation bias is present in our
study. By utilizing a 6-month lag period we have attempted to
alleviate some risk of reverse-causation producing erroneous
results. As with all observational studies, and even randomized
controlled trials (60), eliminating potential confounders in their
entirety is not possible. Nonetheless we attempted to control for
putative prognostic factors by including all variables achieving
or approaching significance at the p = 0.10 level in multivariable
Cox regression in addition to the main variables of interest
(hyperglycemia and glucocorticoid usage). Statin agent dosages
were seldom recorded, and we were therefore unable to establish
a dose-response relationship. However, recent large analyses
(25) have been unsuccessful in establishing this dose-response
relationship, suggesting that statin exposure and survival may be
a binary relationship, if present. Furthermore, our results may
be limited by the fact that patients were not necessarily fasting
when glucose labs were drawn; we attempted to mitigate this by
assessing an extensive amount of glucose values around the time
of treatment, totaling 2870, and representing the greatest number
of data points per patient in a study of this kind. It should be
noted that at least one study has shown cancer patients with a
comorbid diabetes diagnosis to be treated less aggressively than
their healthy counterparts (61). This potential bias is unlikely to
be present as all patients in this study received similar aggressive
treatment. The extensive random sampling within our patient
set assessed purely serum glucose levels regardless of a diabetes
diagnosis. Along these lines, the large number of glucose values
and extensive statistical assessment of competing variables
remains a strength of this analysis.
CONCLUSION
Glucose levels, anti-diabetic medications, and statin usage
were not associated with overall survival, disease-free survival,
distant metastases, or loco-regional control in a robust
retrospective database of NSCLC patients treated with definitive
chemoradiation. While a blood glucose value over 130 mg/dl
trended toward a consistent association with inferior outcomes,
reaching borderline significance for locoregional control and
overall survival, and statin usage trended with improved
locoregional control, glycemic state, statins, and glucose-
modulating medication usage was not associated with outcomes
in multivariable analysis. Prognosis in NSCLC patients may be
less related to metabolic factors than other cancer sites, but high
quality prospective studies are further needed to elucidate the
relationship between glycemic state and outcomes in NSCLC
patients.
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